Safety, tolerability and efficacy of sublingual allergoid immunotherapy with three different shortened up-dosing administration schedules;Sicurezza, tollerabilità ed efficacia dell'immunoterapia sublinguale con allergoide mediante tre diversi schemi posologici

Acta Otorhinolaryngologica Italica

Volumn 30, Issue 3, 2010, Pages 131-137

  Passali, D ^a   Mosges R ^b   Passali, G C ^c   Passali, F M ^d   Ayoko, G ^b   Bellussi, L ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Carbamylated allergoid; Posological schedule; Rhinitis; Sublingual immunotherapy; Up dosing

Indexed keywords

EID: 77955166009     PISSN: 0392100X     EISSN: 1827675X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003;2:CD002893.
2. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141-8.
3. Bousquet J, Malling HJ. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53:1-42.
4. Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group; WHO. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl):S147-S334.
5. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629-32.
6. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001;56:989-92.
7. Di Rienzo V, Pagani A, Parmiani S, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999;54:1110-3.
8. Rossi RE, Monasterolo G. A pilot study of feasibility of ultrarush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005;18:277-85.
9. Grosclaude M, Bouillot P, Alt R, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002;129:248-53.
10. Passalacqua G, Lombardi C, Guerra L, et al. Sublingual immunotherapy: no more doubts. Eur Ann Allergy Clin Immunol 2005;37:314-20.
11. G iordano T, Quarta C, Bruno ME, et al. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. Eur Ann Allergy Clin Immunol 2006;9:310-2.
12. Mistrello G, Brenna O, Roncarolo D, et al. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996;51:8-15.
13. Pfaar O, Klimek L; for the Study Group. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo controlled trial. Ann Allergy Asthma Immunol 2008;100:256-63.
14. Gammeri E, Arena A, D'Anneo R, et al. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 2005;33:142-4.
15. Malling HJ, Lund D, Ipsen H, et al. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006;16:162-8.
16. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9.